Your search for bevacizumab returned 11 results

The approval was based on data demonstrating that the biosimilar product and the reference product were highly similar, and that there were no clinically meaningful differences between the agents.

Alymsys is a vascular endothelial growth factor inhibitor.

Outcomes at 2 years comparable among patients with diabetic macular edema receiving aflibercept monotherapy, bevacizumab first

Vegzelma is a vascular endothelial growth factor inhibitor.

At the end of one year, likelihood of being weaned off treatment was higher for eyes treated with aflibercept versus bevacizumab

The IMbrave050 study included 662 patients with HCC at high risk for recurrence after surgical resection or ablation with curative intent.

The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of October. The chart below provides highlights of key monograph updates made this month (not an inclusive list). Click on the name of the drugs to view the full monographs on eMPR.com. Key: D=Dosing,…

Substantial improvement observed through month 12, which persisted through month 60, but lessened with fewer treatments

Mirvetuximab soravtansine is an antibody-drug conjugate comprised of a FRα-binding antibody, a cleavable linker, and a potent tubulin-targeting agent.

The approval was based on data from the SORAYA trial.